Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafolecimab + sintilimab + chemotherapy after first-line immunotherapy failure in advanced driver-gene-negative non-small cell lung cancer
ChiCTR2400087481Phase 2Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafolecimab and sintilimab in non-small cell lung cancer (NSCLC), sponsored by Beijing Chest Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
tafolecimabsintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400087481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087481.